A Multicenter Evaluation of Different Chemotherapy Regimens in ...

A multicenter phase II study of the efficacy and safety of docetaxel ...

Severe (grade 3/4) neutropenia and thrombocytopenia occurred in 69.2% and 6.2% of patients, respectively. Other common toxicities including peripheral edema ...

A phase II, multicenter evaluation of docetaxel, gemcitabine, and ...

This study was designed to evaluate the efficacy and tolerability of Docetaxel + Gemcitabine in combination with Bevacizumab (D/G/B) in chemotherapy-naïve Stage ...

Differences in the Therapeutic Effect of Chemotherapy Regimens for ...

The median overall survival was 1,037 days in total; it tended to be slightly longer for CDDP+VNR than CBDCA+PTX. Conclusion: Different chemotherapy regimens ...

Multicenter evaluation of breast cancer patients' satisfaction and ...

Among the 1299 participants eligible for this analysis, 53% of participants were undergoing standard post-treatment follow-up while 22 and 17% ...

Multicenter evaluation of the safety and efficacy of radioembolization ...

Results: Patients received a median of 2 (range, 0-6) lines of prior chemotherapy; 35.1% had limited extrahepatic metastases. Median tumor-to-liver ratio and - ...

First Line Chemotherapy with Weekly Docetaxel and Cisplatin in ...

The combination of weekly docetaxel and cisplatin is a well-tolerated treatment modality with encouraging activity and survival outcome in previously untreated ...

an international, multicentre, randomised phase 3 trial - The Lancet

5-year overall survival rates were 80% in the induction chemotherapy with chemoradiotherapy group and 72% in the chemoradiotherapy alone group, ...

Quantitative comparison of the efficacies and safety profiles of three ...

In third-generation chemotherapy drugs, no other drug is better tolerated than vinorelbine. Tolerance of the drug did not result in a decrease ...

Multicenter Retrospective Analysis of Chemotherapy for... : Pancreas

The overall response rate in the patients who received first-line chemotherapy were 7% and 38%, respectively, and the median overall survival was 13.2 months.

Three Weekly Versus Weekly Cisplatin: Comparison of two Different ...

Introduction: Chemoradiotherapy (CRT) with concurrent cisplatin-based chemotherapy is the treatment of choice of locally advanced head and neck ...

djv368.pdf - Oxford Academic

... different induction chemotherapy regimens, followed by radiotherapy or chemoradiotherapy for larynx preservation. Tissue. TPF, %. PF, %. P ...

Esophageal Cancer Treatment Protocols - Medscape Reference

Radiation therapy is often given with chemotherapy. External beam radiation therapy (EBRT) is used. Proton beam therapy may be used in the ...

Multicenter evaluation of neoadjuvant and induction gemcitabine ...

Purpose Cisplatin-based chemotherapy followed by radical cystectomy (RC) is recommended in patients with muscle-invasive bladder cancer ...

final results of the GIMEMA LAL1509 protocol | Haematologica

Nowadays, TKI with,, or without,,, systemic chemotherapy in induction represent the gold standard approach. TKI-based schemes have led to a ...

Lack of durable disease control with chemotherapy for mycosis ...

Patients received a median of 3 lines of therapy (range 1-13), resulting in 709 treatment episodes. Twenty-eight treatment modalities were analyzed. The median ...

Comparison of different treatment strategies for T3N1-3 stage gastric ...

Chemotherapy was administered to the majority of patients (N1: 81.57%; N2: 79.33%; N3: 72.59%), with minimal disparity observed in the ...

A Multicenter Randomized Controlled Study of Paclitaxel plus ...

As for the paclitaxel plus carboplatin protocol (n = 190), 163 patients (85.8%) received all four cycles of chemotherapy. During the whole treatment course, 25 ...

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for ...

The current standard chemotherapy for extensive small-cell lung cancer — a regimen of etoposide and cisplatin or this combination alternating with a combination ...

A multicenter phase II study of the efficacy and safety of docetaxel ...

18-20. In a recent phase III Eastern. Cooperative Oncology Group Trial comparing 4 different chemotherapy arms,31 the subgroup of ... Comparison of four ...

HEAD AND NECK CANCER TREATMENT REGIMENS (Part 1 of 5)

Concurrent radiotherapy and chemotherapy every other week for total treatment ... Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy ...